This article is more than 5 years old. Information may no longer be current.

Refocus completes patient enrollment for potential presbyopia treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Enrollment is complete for a phase 3 clinical trial of the VisAbility Micro-Insert System for treatment of presbyopia, according to press release from Refocus Group. Three-hundred and sixty subjects are enrolled at 13 clinical trial sites in the U.S.

The company also announced it has secured $15 million in new financing from MedCare Investments Funds and WP Global Partners.

The VisAbility Micro-Insert procedure entails insertion of four micro-thin inserts below the surface of the sclera, without altering the cornea or natural lens. It is intended to restore near vision without compromising distance vision or depth perception, according to the release.